Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ10591MR)

This product GTTS-WQ10591MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets ANGPT2 gene. The antibody can be applied in Solid tumors, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001118887.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285
UniProt ID O15123
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2, LY-3127804(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ10591MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ4605MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ9651MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ5561MR IVTScrip™ mRNA-Anti-CD33, CDP-771(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CDP-771
GTTS-WQ10032MR IVTScrip™ mRNA-Anti-FN, L19-131 I(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA L19-131 I
GTTS-WQ5813MR IVTScrip™ mRNA-Anti-CD40, CFZ-533(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CFZ-533
GTTS-WQ12550MR IVTScrip™ mRNA-Anti-Canlupfam NGF, NV-01(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NV-01
GTTS-WQ10468MR IVTScrip™ mRNA-Anti-SOST, LY2541546(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA LY2541546
GTTS-WQ4836MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW